As announced on May 19, 2021, CELLINK AB (publ) (“CELLINK”) entered into an agreement to acquire the German company Nanoscribe Holding GmbH (“Nanoscribe”), an award-winning company focusing on development of high-precision 3D printers based on Two-Photon Polymerization technology (“2PP”). CELLINK has on this day completed the acquisition of all Nanoscribe-shares.
The preliminary purchase price for all shares amounted to approximately €36.9 million, which is subject to adjustment for net cash/debt and deviation from normalized working capital according to the Closing Date Balance Sheet, and of which approximately €12.2 million was paid in 301,332 newly issued shares of series B in CELLINK at a price of SEK 411.34 per share (the “Consideration Shares”) and the reminder in cash. The price for the Consideration Shares has been determined by the volume weighted average price of CELLINK shares of series B on Nasdaq Stockholm ten trading days preceding signing i.e., on May 19, 2021. The Consideration Shares are expected to be registered by the Swedish Companies Registration Office during the month of June and will correspond to approximately 0.5 percent of the share capital and approximately 0.4 percent of the votes in CELLINK.
“By combining CELLINK’s and Nanoscribe’s revolutionary technologies, we can offer market-leading 2PP products for a wide range of customer segments. Nanoscribe’s technology empowers cutting edge science and drives industrial innovations in a wide variety of sectors such as bioprinting, microfluidics, micro-optics, micromechanics, biomedical engineering, and integrated photonics technologies. The life science industry is currently going through a very exciting transformation where many processes and technologies are being miniaturized to increase throughput and to reduce costs, where price of reagents is a major bottle neck for sequencing. One example is the sample preparation steps for single cell genomics applications. With Nanoscribe’s technology, we stay competitive in this transformation and this enables us to miniaturize devices for a wide range of applications, resulting in capabilities to further expand our offering in bioprinting and consumables across all business areas.” Erik Gatenholm, CEO, CELLINK.
For further information on the acquisition and about Nanoscribe, please see the press release which was published on May 19, 2021.
For further information, please contact:
|Erik Gatenholm, CEO
Phone (Sweden): +46 73 267 00 00
Phone (US): +1 (650) 515 5566
|Gusten Danielsson, CFO
Phone (Sweden): +46 70 991 86 04
Phone (US): +1 (857) 332 2138
The information was submitted for publication, through the agency of the contact persons set out above, on May 31, 2021 at 18:15 (CEST).
Founded in 2016, CELLINK is the leading bioconvergence company in the world that provides technologies, products and services to create, understand and master biology. With a focus on the application areas of bioprinting, multiomics, cell line development, and diagnostics, the company develops and markets innovative technologies that enable researchers in the life sciences to culture cells in 3D, perform high-throughput drug screening and print human tissues and organs for the medical, pharmaceutical, and cosmetic industries. CELLINK’s products are trusted by more than 2,000 laboratories, including ones at all the top 20 pharmaceutical companies, are being used in more than 65 countries, and have been cited in more than 1,700 publications. CELLINK is creating the future of medicine. CELLINK is listed on the Nasdaq the Stockholm under CLNK B. www.cellink.com/investors